Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Innocenti

Showing results (121-130 of 186) with videos related to

Pageof 19
Sort By:
Elife|April 30, 2024
Germline <i>cis</i> variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (<i>DPYD</i>)Ting Zhang, Alisa Ambrodji, Huixing Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)Hedy Lee Kindler, Donna Niedzwiecki, Donna Hollis, et al.
Cancer Medicine|July 29, 2016
Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Ace J Hatch, Alexander B Sibley, Mark D Starr, et al.
BMC Genomics|May 14, 2024
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)Julia C F Quintanilha, Alexander B Sibley, Yingmiao Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2011
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancerDylan M Glubb, Elisa Cerri, Alexandra Giese, et al.
The Pharmacogenomics Journal|April 28, 2022
KDR genetic predictor of toxicities induced by sorafenib and regorafenibJulia C F Quintanilha, Susan Geyer, Amy S Etheridge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2019
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)Heinz-Josef Lenz, Fang-Shu Ou, Alan P Venook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2019
Reply to S. SorscherFederico Innocenti, Fang-Shu Ou, Xueping Qu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2019
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient OutcomeFederico Innocenti, Fang-Shu Ou, Xueping Qu, et al.
The Oncologist|June 5, 2024
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancerHanna K Sanoff, Allison M Deal, Jai Patel, et al.
Pageof 19

Showing results (121-130 of 186) with videos related to

Sort By:
Pageof 19
Elife|April 30, 2024
Germline <i>cis</i> variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (<i>DPYD</i>)Ting Zhang, Alisa Ambrodji, Huixing Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)Hedy Lee Kindler, Donna Niedzwiecki, Donna Hollis, et al.
Cancer Medicine|July 29, 2016
Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Ace J Hatch, Alexander B Sibley, Mark D Starr, et al.
BMC Genomics|May 14, 2024
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)Julia C F Quintanilha, Alexander B Sibley, Yingmiao Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2011
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancerDylan M Glubb, Elisa Cerri, Alexandra Giese, et al.
The Pharmacogenomics Journal|April 28, 2022
KDR genetic predictor of toxicities induced by sorafenib and regorafenibJulia C F Quintanilha, Susan Geyer, Amy S Etheridge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2019
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)Heinz-Josef Lenz, Fang-Shu Ou, Alan P Venook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2019
Reply to S. SorscherFederico Innocenti, Fang-Shu Ou, Xueping Qu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2019
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient OutcomeFederico Innocenti, Fang-Shu Ou, Xueping Qu, et al.
The Oncologist|June 5, 2024
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancerHanna K Sanoff, Allison M Deal, Jai Patel, et al.
Pageof 19